Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Angioimmunoblastic T Cell Lymphoma
Status:
Recruiting
Trial end date:
2030-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter prospective single arm phase II study. The purpose of this study is to
evaluate the safety and efficiency of azacytidine combined with CAOLD Regimen in the
treatment of relapsed/refractory angioimmunoblastic T-cell lymphoma.